Found 15 clinical trials
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …
- 0 views
- 19 Feb, 2024
- 51 locations
Study in Subjects With Relapsed/Refractory Follicular Lymphoma
This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …
- 0 views
- 19 Feb, 2024
- 8 locations
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Since the study is "blinded," patients and their doctors will not know whether a patient gets brentuximab vedotin or placebo. All patients in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.
- 0 views
- 19 Feb, 2024
- 1 location
Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
In this study temelimab is administered subsequently to rituximab therapy, i.e. no co-administration of rituximab and temelimab is done in this study.
- 0 views
- 19 Feb, 2024
- 1 location
Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma
It is a multicenter, open-Label, randomised phase 2 study to compare the efficacy and safety study of R2-MTX chemotherapyLenalidomide, Rituximab and Methotrexatewith R-MTX chemotherapyRituximab and Methotrexate as first-line regimens in the treatment of newly diagnosed primary central nervous system lymphoma.2-year Progression free survival (PFS) is the primary endpoint.
- 0 views
- 19 Feb, 2024
- 1 location
CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
There is little experience of using rituximab in pediatric ALL thus a CCCG Relapsed ALL 2017 Study will perform the study assessing the remission rate and MRD response of CD20+ ALL treated with rituximab.
- 0 views
- 19 Feb, 2024
- 1 location
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …
- 0 views
- 19 Feb, 2024
- 1 location
Venetoclax SL-401 and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
This phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant protein consisting of IL-3 linked to a …
- 0 views
- 19 Feb, 2024
- 1 location
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
However; the prolonged use of high dose steroids carries significant side effects. A recent randomized trial has proved the efficacy of Rituximab, a monoclonal anti-CD20 antibody against B-lymphocytes, as an efficacious therapy for pemphigus. Early use of rituximab was associated with better clinical outcomes, hence combination treatment of rituximab and …
- 0 views
- 19 Feb, 2024
- 1 location
Acalabrutinib Lenalidomide and Rituximab for the Treatment of CD20 Positive Stage III-IV Grade 1-3a Follicular Lymphoma
Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow …
- 0 views
- 19 Feb, 2024
- 1 location
- 1
- 2